Contineum Therapeutics, Inc.

NasdaqGS:CTNM Stock Report

Market Cap: US$371.5m

Contineum Therapeutics Past Earnings Performance

Past criteria checks 0/6

Contineum Therapeutics has been growing earnings at an average annual rate of 30.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 31.8% per year.

Key information

30.2%

Earnings growth rate

111.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate31.8%
Return on equity-16.9%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Oct 07
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Jun 13

Revenue & Expenses Breakdown

How Contineum Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:CTNM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-291132
30 Jun 240-20929
31 Mar 24500831
31 Dec 23503727
30 Sep 2350-3723
31 Dec 220-24716

Quality Earnings: CTNM is currently unprofitable.

Growing Profit Margin: CTNM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CTNM's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CTNM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTNM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: CTNM has a negative Return on Equity (-16.87%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:40
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Contineum Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Jeff HungMorgan Stanley
Luke DavisRBC Capital Markets